The 2025 market withdrawal of Ocaliva (obeticholic acid) is one of the most significant developments PBC patients have faced in years, reshaping both treatment options and legal rights. This update from AWKO explains the full timeline, why the withdrawal matters for patient safety, and how it strengthens potential lawsuits for those harmed by Ocaliva-related liver injury.
Timeline of Ocaliva’s Withdrawal
Ocaliva received accelerated FDA approval in 2016 as a second-line treatment for adults with Primary Biliary Cholangitis (PBC) who had an inadequate response to or intolerance of ursodeoxycholic acid. Over time, however, mounting safety data revealed serious liver-related complications, prompting increasingly strict regulatory actions.
Key events in the lead-up to withdrawal include:
- In 2021, the FDA restricted Ocaliva’s use and updated prescribing information after identifying 25 cases of serious liver injury, including in patients without advanced cirrhosis.
- In late 2024, the FDA announced that serious liver injury was occurring even in patients without cirrhosis and required frequent liver test monitoring for anyone taking Ocaliva.
- A required post‑marketing trial (Study 747‑302) showed higher rates of liver transplant and death among Ocaliva users compared with placebo, even in carefully selected patients thought unlikely to experience liver injury.
On September 10–11, 2025, Intercept Pharmaceuticals—Ocaliva’s manufacturer—submitted a formal request asking the FDA to withdraw approval of Ocaliva’s New Drug Application and announced a voluntary withdrawal of Ocaliva from the U.S. market. The decision followed an FDA request after regulators reviewed clinical data showing increased risks of serious liver injury, transplant, and death.
Following a short transition period for patients to consult their physicians about alternatives, Ocaliva was officially removed from the U.S. commercial market on November 14, 2025. All Intercept‑sponsored U.S. clinical trials involving obeticholic acid were placed on clinical hold at the same time.
Why a Market Withdrawal Matters
A full market withdrawal is one of the most serious regulatory outcomes a drug can face, sitting alongside black box warnings and boxed contraindications as a sign of high risk. While Intercept has emphasized that the withdrawal was not due to manufacturing defects or contamination, the official communications from regulators and payers point directly to safety concerns, particularly serious liver injury in PBC patients.
According to multiple notices issued by health plans and the FDA, the decision to withdraw Ocaliva followed a determination that the overall benefit–risk profile no longer justified its continued use. Regulators cited:
- A documented risk of serious liver injury, including liver failure, among Ocaliva‑treated PBC patients.
- Cases of liver transplant, transplant evaluation/listing, and liver‑related deaths in both cirrhotic and non‑cirrhotic patients.
- Evidence from confirmatory clinical trials showing an elevated combined risk of liver transplant or death for patients on Ocaliva compared with placebo.
In other words, the 2025 market withdrawal is not simply a business decision—it is the culmination of years of adverse event reporting, FDA safety communications, label restrictions, and a final conclusion that the drug’s risks overshadow its benefits for PBC.
Connection to Patient Injury
For PBC patients and families, the Ocaliva withdrawal is directly tied to real-world harm. Reports accumulated over several years describing severe liver complications in people taking Ocaliva to treat an already fragile liver condition.
Regulatory and legal investigations have highlighted patterns such as:
- Patients developing new or worsening signs of liver failure—jaundice, ascites (abdominal swelling), confusion, bleeding, and profound fatigue—after starting Ocaliva.
- Serious outcomes including emergency hospitalizations, liver transplants, or death in people treated for PBC with Ocaliva, some of whom did not have cirrhosis at baseline.
- Cases where Ocaliva allegedly continued despite progression of liver disease, in situations where the drug should have been stopped under updated prescribing guidance.
The FDA’s own communications noted that, among patients for whom Ocaliva was indicated in a post‑marketing study, 7 of 81 receiving Ocaliva required liver transplant compared with 1 of 68 patients on placebo, and 4 patients on Ocaliva died versus 1 on placebo. Between 2021 and late 2024, regulators also identified 20 post‑restriction cases of Ocaliva‑treated patients who required transplant, were evaluated or listed for transplant, or suffered liver‑related death.
By 2025, this body of evidence painted a clear picture: Ocaliva, a drug designed to help manage PBC and protect the liver, was strongly associated with some of the most severe liver outcomes possible. That connection between the drug and real‑world injury is what ultimately drove FDA to request, and Intercept to accept, a full withdrawal from the market.
How the Withdrawal Affects Current PBC Patients
For patients who were still on Ocaliva at the time of the withdrawal, the most immediate impact is the need to transition to alternative treatment options under the guidance of a hepatologist or gastroenterologist. Intercept and major health plans advised patients to contact their treating clinicians promptly to discuss discontinuation and replacement therapies.
Notices to patients and providers highlighted several key steps:
- Ocaliva would no longer be dispensed after November 14, 2025; pharmacies and insurers have been informed to stop filling prescriptions.
- Patients should not stop any liver medication on their own but must consult their physician to reassess PBC management, including ongoing liver function monitoring and alternative medications or clinical trial options.
- Any new or worsening liver‑related symptoms—such as jaundice, dark urine, abdominal pain, or confusion—should be reported urgently to healthcare providers and can also be reported as adverse events to Intercept or the FDA.
For those who previously took Ocaliva and experienced serious liver complications, the withdrawal also serves as a powerful confirmation that their experiences were not isolated. Many patients have begun reaching out to specialized law firms to explore whether they may have legal claims related to liver failure, transplant, or wrongful death linked to the drug.
Legal Implications: Strengthening Failure‑to‑Warn Claims
From a legal perspective, the 2025 Ocaliva market withdrawal significantly bolsters arguments in failure‑to‑warn and defective‑drug lawsuits against the manufacturer.
Several legal implications stand out:
- Evidence of Serious Risk: A complete market withdrawal, especially one requested by the FDA due to safety concerns, is strong evidence that regulators concluded the drug posed unacceptable risks, including liver failure, transplant, and death.
- Support for Causation: Safety analyses and post‑marketing trials used by the FDA to justify the withdrawal—showing higher rates of transplant and death in Ocaliva users—support individual plaintiffs’ arguments that Ocaliva was a likely cause of their liver injury rather than just the underlying PBC.
- Timing and Delay: Plaintiffs can argue that Intercept and regulators knew or should have known about serious risks years before the 2025 withdrawal, pointing to black box warnings (added in 2018), label restrictions (2021), and ongoing safety communications (2024–2025). If a patient’s injury occurred before the withdrawal, their attorneys may contend that warnings were inadequate or too late.
Many law firms investigating Ocaliva are explicitly citing the withdrawal as a turning point that strengthens pending and future cases. The fact that the drug’s approval itself was surrendered at the company’s request—after an FDA advisory committee had already voted against full approval—can be used to highlight an unfavorable benefit–risk profile that persisted despite earlier safety measures.
What This Means If You Took Ocaliva
If you or a loved one took Ocaliva for PBC and later developed serious liver problems, the 2025 withdrawal changes the landscape of your potential legal claim.
You may want to consider legal evaluation if you:
- Were diagnosed with liver failure, acute liver decompensation, or advanced cirrhosis after using Ocaliva.
- Required a liver transplant or were evaluated or listed for transplant while on or after taking Ocaliva.
- Lost a family member to liver‑related complications while they were being treated with Ocaliva for PBC.
- Were treated during the years when safety warnings were evolving, but you feel you were not fully informed of the known risks.
In these situations, lawyers may investigate whether Intercept failed to provide adequate warnings, minimized risk signals, or continued to promote Ocaliva despite accumulating evidence of serious liver injury. The withdrawal and underlying safety data will be central pieces of evidence in such litigation.
Why Specialized Pharmaceutical Counsel Matters
Cases involving withdrawn drugs, complex safety data, and years of regulatory back‑and‑forth require law firms that focus specifically on pharmaceutical litigation. Attorneys handling Ocaliva claims must be able to:
- Interpret FDA documents, advisory committee findings, post‑marketing study results, and European regulatory decisions that preceded the U.S. withdrawal.
- Work with hepatology and pharmacology experts to demonstrate that Ocaliva more likely than not contributed to a specific patient’s liver failure or death.
- Navigate multidistrict litigation structures and coordinate with other firms handling Ocaliva cases nationwide.
Patients and families should seek firms that are already investigating or filing Ocaliva lawsuits, rather than general practitioners with limited drug‑injury experience.
See If Your Ocaliva Injury Qualifies
The Ocaliva market withdrawal is a turning point for PBC patients and their families, but it also signals that time is of the essence. Statutes of limitations can bar claims if they are not filed within a set number of years after an injury—or after the connection between the injury and the drug should reasonably have been discovered.
AWKO is actively reviewing potential Ocaliva cases for people who:
- Suffered serious liver injury, transplant, or liver‑related death after Ocaliva use.
- Were prescribed Ocaliva between its 2016 approval and the 2025 market withdrawal, especially during the years when new FDA safety alerts and restrictions were being issued.
A free, confidential case review can help determine whether you may have a claim and how the 2025 withdrawal and underlying FDA findings could support your case.
If you or a loved one took Ocaliva and later experienced severe liver complications, contact AWKO today for a no‑cost consultation. Our team can evaluate your medical history, explain how the Ocaliva withdrawal impacts your legal options, and help you pursue the compensation and accountability you deserve.